-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ESQRiwJpH6jso0WMAfL/ofOxJpCpPalM9ARuoLOzp8MEv9cqpS3PSqtzPGrlz02R L6Z3EpoiFcrQ43KNC4rScw== 0000950144-05-010320.txt : 20051013 0000950144-05-010320.hdr.sgml : 20051013 20051013171150 ACCESSION NUMBER: 0000950144-05-010320 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20051013 DATE AS OF CHANGE: 20051013 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NOVAVAX INC CENTRAL INDEX KEY: 0001000694 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222816046 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-48948 FILM NUMBER: 051137280 BUSINESS ADDRESS: STREET 1: 508 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 4849131200 MAIL ADDRESS: STREET 1: 508 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: KING PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001047699 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 541684963 STATE OF INCORPORATION: TN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 501 FIFTH ST CITY: BRISTOL STATE: TN ZIP: 37620 BUSINESS PHONE: 4239898000 MAIL ADDRESS: STREET 1: 501 FIFTH ST CITY: BRISTOL STATE: TN ZIP: 37620 SC 13D/A 1 g97588sc13dza.htm NOVAVAX, INC./KING PHARMACEUTICALS, INC. NOVAVAX, INC./KING PHARMACEUTICALS, INC.
 

OMB APPROVAL
OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response...15


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 4)*

Novavax, Inc.

(Name of Issuer)

Common Stock, $0.01 par value

(Title of Class of Securities)

670002104

(CUSIP Number)

Jonathan L. Kravetz, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, MA 02111
(617) 542-6000

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

September 9, 2005

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.


 

             
CUSIP No. 670002104

  1. Name of Reporting Person:
King Pharmaceuticals, Inc.
I.R.S. Identification Nos. of above persons (entities only):
54-1684963

  2. Check the Appropriate Box if a Member of a Group (See Instructions):
    (a) o  
    (b) o  

  3. SEC Use Only:

  4. Source of Funds (See Instructions):
Not Applicable

  5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e): x

  6. Citizenship or Place of Organization:
Tennessee

Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
7. Sole Voting Power:
0

8. Shared Voting Power:
0

9. Sole Dispositive Power:
0

10.Shared Dispositive Power:
0

  11.Aggregate Amount Beneficially Owned by Each Reporting Person:
0

  12.Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):
o

  13.Percent of Class Represented by Amount in Row (11):
0%

  14.Type of Reporting Person (See Instructions):
CO

Page 2 of 8 pages


 

This Amendment No. 4 to the Schedule 13D relating to shares of common stock, $0.01 par value (the “Common Stock”), of Novavax, Inc., a Delaware corporation (the “Issuer”), is being filed by King Pharmaceuticals, Inc., a Tennessee corporation (“King”) to report a decrease in its beneficial ownership of the Common Stock of the Issuer and to otherwise amend Items 1, 2, 4, 5, 6 and 7 of the Schedule 13D originally filed on December 29, 2000, as amended.
The original Schedule 13D was filed on December 29, 2000 reporting the initial acquisition by King of the Issuer’s 4% Convertible Senior Note No. 1 dated December 19, 2000 (the “First Note”).
Amendment No. 1 to the Schedule 13D was filed on September 19, 2001 to report the initial acquisition by King of the Issuer’s 4% Convertible Senior Note No. 2 dated September 7, 2001 (the “Second Note”) and the Issuer’s 4% Convertible Senior Note No. 3 dated September 7, 2001 (the “Third Note”).
Amendment No. 2 to the Schedule 13D was filed on July 24, 2002 to report the initial acquisition by King of the Issuer’s 4% Convertible Senior Note No. 4 dated June 26, 2002 (the “Fourth Note”).
Amendment No. 3 to the Schedule 13D was filed on August 26, 2004 to report a decrease in King’s beneficial ownership of the Common Stock of the Issuer.
Item 1. Security and Issuer
The title of the class of equity securities to which this statement relates is the Common Stock of the Issuer owned by King. The Issuer’s principal executive offices are located at 508 Lapp Road, Malvern, Pennsylvania 19355.
Item 2. Identity and Background
King, the entity filing this Amendment No. 4 to the Schedule 13D, is a Tennessee corporation, and its principal business address and principal office address is 501 Fifth Street, Bristol, Tennessee 37620. King is a vertically integrated pharmaceutical company that develops, manufactures, markets and sells branded prescription pharmaceutical products.
Each executive officer and each director of King is a citizen of the United States, except for Elizabeth M. Greetham who is a British citizen. The name, business address and present principal occupation of each executive officer and director is set forth in Appendix A to this Amendment No. 4 to the Schedule 13D and incorporated herein by reference.
Other than executive officers and directors, there are no persons or corporations controlling or ultimately in control of King.
Neither King nor any of its executive officers or directors has, during the last five years, (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining
Page 3 of 8 pages

 


 

future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation of such laws, except as follows. Mr. John A. A. Bellamy, our Executive Vice President of Legal Affairs and General Counsel, was convicted of a misdemeanor in the State of Tennessee related to the offenses of driving under the influence and while license was suspended or revoked. He is currently on a leave of absence.
Item 3. Source and Amount of Funds or Other Consideration
     Not applicable.
Item 4. Purpose of Transaction
     Not applicable.
Item 5. Interest in Securities of the Issuer
  (a)   The calculations in this Schedule 13D are based upon 43,553,876 shares of Common Stock issued and outstanding as of July 29, 2005 (based on disclosures made by the Issuer in its Form 10-Q for the quarterly period ended June 30, 2005). King is now the beneficial owner of zero shares of the Issuer’s Common Stock, comprising zero percent of the issued and outstanding shares of Common Stock of the Issuer. The foregoing calculation is made pursuant to Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended.
 
  (b)   King no longer owns any shares of Common Stock and, therefore, has no power (sole or shared) to vote or direct the vote, or dispose or direct the disposition, of such shares of Common Stock.
 
  (c)   King has effected the following sales of Common Stock during the past 60 days:
                         
Date of Sale   Number of Shares   Price per Share ($)   Manner of Transaction
8/30/05
    1,000,000       2.0450     Open Market Sale
8/31/05
    331,000       1.5227     Open Market Sale
9/1/05
    569,300       1.5768     Open Market Sale
9/6/05
    159,889       1.3206     Open Market Sale
9/7/05
    700,000       1.4302     Open Market Sale
9/7/05
    100,000       1.4007     Open Market Sale
9/9/05
    1,240,742       1.5268     Open Market Sale
  (d)   King affirms that no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of the Issuer’s Common Stock that had been beneficially owned by King.
 
  (e)   King ceased to be the beneficial owner of more than five percent of the Common Stock on September 6, 2005.
Page 4 of 8 pages

 


 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
As noted in Amendment No. 3 to the Schedule 13D, the Issuer has, pursuant to a Registration Rights Agreement dated as of July 19, 2004, prepared and filed a registration statement related to the shares of its Common Stock beneficially owned by King. Except as set forth in this Amendment No. 4 to the Schedule 13D, neither King, nor to King’s knowledge, any of its directors or executive officers has any other contract, arrangement, understanding or relationship (legal or otherwise) with any person with respect to any securities of the Issuer.
Item 7. Material to be Filed as Exhibits
Registration Rights Agreement by and between Novavax, Inc. and King Pharmaceuticals, Inc. dated July 19, 2004 (incorporated herein by reference to Amendment No. 3 to the Schedule 13D filed by King with respect to the Issuer on August 26, 2004 [File No. 005-48948]).
Page 5 of 8 pages

 


 

SIGNATURE
     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
  October 10, 2005
 
(Date)
    KING PHARMACEUTICALS, INC.
    /s/ Brian A. Markison
 
(Signature)
    President and Chief Executive Officer
 
(Name/Title)
Page 6 of 8 pages

 


 

APPENDIX A
DIRECTORS AND EXECUTIVE OFFICERS
KING PHARMACEUTICALS, INC.
The names, business addresses and present principal occupations of the directors and executive officers of King Pharmaceuticals, Inc. (“King”) are set forth below. If no business address is given, the director’s or executive officer’s business address is 501 Fifth Street, Bristol, Tennessee 37620. All directors and executive officers listed below are citizens of the United States, except for Elizabeth M. Greetham who is a British citizen.
     
    Present Principal Occupation or Employment and
Name   Business Address
Brian A. Markison
  President, Chief Executive Officer and Director
 
   
Joseph Squicciarino
  Chief Financial Officer
 
   
Stephen J. Andrzejewski
  Chief Commercial Officer
 
   
Eric J. Bruce
  Corporate Head — Technical Operations
 
   
James E. Green
  Executive Vice President, Corporate Affairs
 
   
John A. A. Bellamy
  Executive Vice President, Legal Affairs and General Counsel
 
   
Earnest W. Deavenport, Jr.
  Director of King
 
  Former Chairman of the Board and Chief Executive Officer of Eastman Chemical Company
 
  373 Laurel Ridge Lane
 
  Banner Elk, NC 28604
 
   
Elizabeth M. Greetham
  Director of King
 
  Chief Executive Officer and President , ACCL Financial Consultants, Ltd.
 
  Bye-Ways
 
  4 Tucker Towne Rd.
 
  St. Georges Parish, Bermuda
 
   
Gregory D. Jordan
  Director of King
 
  President of King College
 
  1350 King College Road
 
  Briston, TN 37620
 
   
R. Charles Moyer
  Director of King
 
  Dean, College of Business and Public Administration
 
  University of Louisville
 
  Louisville, KY 40292
 
   
Philip M. Pfeffer
  Director of King
 
  President and Chief Executive Officer of Treemont Capital, Inc.
 
  701 Murfreesboro Rd.
 
  Nashville, TN 37210

Page 7 of 8 pages


 

     
    Present Principal Occupation or Employment and
Name   Business Address
D. Greg Rooker
  Director of King
 
  Former Owner and President of Family Community Newspapers of Southwest Virginia, Inc.
 
  Co-Founder of The Jason Foundation
 
  P.O. Box 430
 
  Radford, VA 24143
 
   
Ted G. Wood
  Director and Non-Executive Chairman of the Board of King
 
  Former Vice Chairman of The United Company
 
  23196 Virginia Trail
 
  Bristol, VA 24202
Page 8 of 8 pages

 

-----END PRIVACY-ENHANCED MESSAGE-----